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Prognosis of Resected Non-Small Cell Lung Cancer Patients
with Intrapulmonary Metastases
Kanji Nagai, MD,* Yasunori Sohara, MD,† Ryosuke Tsuchiya, MD,‡ Tomoyuki Goya, MD,§
and Etsuo Miyaoka, PhD, for The Japan Lung Cancer Registration Committee
Background: In the current TNM staging system revised in 1997
for lung cancer, intrapulmonary metastases (PM) are classified into
two categories: PM1 (in the same lobe of the primary tumor),
designated as T4; and PM2 (in a different lobe), as M1. There have
been no large-scale analyses on PM in non-small cell lung cancer
(NSCLC) patients. We collected data nationwide in Japan for 7408
lung cancer patients undergoing surgical resection during a single
year, 1994. We analyzed the long-term survival of NSCLC patients
to evaluate the prognostic impact of PM in relation to other prog-
nostic factors.
Method: Medical records of 6525 NSCLC patients undergoing
surgical resection during a single year, 1994, were analyzed as a
subset work of the Japanese Joint Committee of Lung Cancer
Registry. The committee sent a questionnaire on outcome and
clinicopathological profiles to 303 institutions.
Results: There were 6080 PM0 (no PM), 317 PM1, and 128 PM2
patients. The 5-year survival rates were 55.1% for PM0 patients,
26.8% for PM1, and 22.5% for PM2 patients, respectively. The
differences in survival between patients with PM0 and PM1 and
between patients with PM0 and PM2 were significant (p  0.001,
respectively); the difference in survival was not significant between
patients with PM1 and PM2 (p  0.298). In R0 and N0 patients,
survival differences were similar for PM0, PM1, and PM2 patients.
Significant survival difference was detected between T3 and PM1
(p  0.0317) and between PM1 patients and T4 patients excluding
PM1 (p  0.0083). The 5-year survival rates of PM2 patients and
M1 patients excluding PM2 were 22.5% and 20.5%, respectively,
and there was no significant difference between the groups (p 
0.434).
Conclusion: There was no significant survival difference between
NSCLC patients with PM1 and PM2. The survival of patients with
PM1 was between that of the T3 and T4 patients excluding PM1.
Key Words: Non-small cell lung cancer, Intrapulmonary metasta-
ses, Prognosis, TNM staging system.
(J Thorac Oncol. 2007;2: 282–286)
In 1989, Deslauriers et al.1 described intrapulmonary metas-tasis (PM) in patients with non-small cell lung cancer
(NSCLC) as satellite nodules, concluding that patients with
these lesions should be classified as stage IIIA in the TNM
staging system. In 1992, the Union Internationale Contre le
Cancer (UICC [International Union Against Cancer]) and the
American Joint Committee on Cancer revised the TNM
classification, and the T factor of lung cancer with PM was
upstaged as a local progression.2,3 T factor was upgraded by
a single unit if PM was located in the primary lobe, and it was
classified as T4 if the PM was located in other lobes of the
ipsilateral lung. When the TNM staging system was revised
in 1997 for lung cancer, PM was designated as T4 if it was in
the same lobe of the primary tumor (PM1) and as M1 if it was
in a different lobe (PM2).4
Since then, there have been no large-scale survival
analyses on NSCLC patients with PM. We collected data
nationwide in Japan for 7408 lung cancer patients undergoing
surgical resection during a single year, 1994.5 We retrospec-
tively analyzed the survival of these patients to evaluate the
prognostic impact of PM in relation to other prognostic
factors.
PATIENTS AND METHODS
As described previously,5 the Japanese Joint Commit-
tee of Lung Cancer Registry sent a questionnaire in 1995 to
320 Japanese institutions, asking them to report outcomes and
clinicopathological profiles for patients who underwent pri-
mary lung cancer resection in 1994. Data for 7408 patients
were collected from 303 institutions. In 2001, the joint
committee sent a questionnaire to these institutions to acquire
clinicopathological profiles and outcome. The following 27
items were included in the questionnaire: gender, age, clinical
(c-) T, c-N, c-M, c-stage, preoperative treatment, surgical
procedure, extent of lymph node dissection, curability, resid-
ual tumor, primary site by lobe, tumor diameter, histology,
organ invasion, pleural involvement, pleural dissemination,
PM, pleural cytology, pathological (p-) T, p-N, p-M, p-stage,
location of nodal metastasis, survival time recurrence, and
cause of death. Recurrent or multiple lung cancers were not
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included in this registry. There were replies from the 303
institutions for all 7408 patients.
This study focused on adenocarcinoma, squamous cell
carcinoma, large cell carcinoma, and adenosquamous carci-
noma patients, excluding small cell lung cancers, low-grade
tumors, and other rare histologies, totaling 6644 patients.
Because of incomplete data on PM status, 119 patients were
excluded, and the remaining 6525 patients were enrolled in
this study.
Statistical Analysis
Cumulative survival rates were calculated by Kaplan–
Meier estimation, using the date of surgical resection as the
starting point and the date of death from any cause or the last
TABLE 1A. Patient Characteristics
PM0 PM1 PM2 M1 (excluding PM2)
No. 6080 (91.49%) 317 (4.8%) 128 (1.9%) 120 (1.8%)
Age 65  10 65  10 63  10 60  11
Sex
Male 4257 (70%) 208 (65.6%) 69 (53.9%) 88 (73.3%)
Female 1792 (29.5%) 108 (34.1%) 59 (46.1%) 32 (26.7%)
DNA 31 (0.5%) 1 (0.3%) — —
Type of operation
Pneumonectomy 512 (8.4%) 35 (11%) 26 (20.3%) 16 (13.3%)
Lobectomy 5208 (85.7%) 265 (83.6%) 84 (65.6%) 90 (75%)
Segmentectomy 157 (2.6%) 3 (0.9%) 8 (6%) 3 (2.5%)
Wedge resection 157 (2.6%) 11 (3.5%) 9 (7%) 9 (7.5%)
DNA 46 (0.8%) 3 (0.9%) 1 (1%) 2 (1.7%)
Curability
R0 5529 (90.9%) 232 (73.2%) 77 (60.2%)
R1 256 (4.2%) 34 (10.7%) 7 (5.5%)
R2 187 (3.1%) 41 (12.9%) 38 (29.7%)
RX 58 (1%) 7 (2.2%) 5 (3.9%)
DNA 50 (0.8%) 3 (0.9%) 1 (0.8%)
DNA, data not available.
TABLE 1B. Patient Characteristics
PM0 PM1 PM2 M1 (excluding PM2)
No. 6080 (91.5%) 317 (4.8%) 128 (1.9%) 120 (1.8%)
Histology
Adenocarcinoma 3522 (57.9%) 201 (63.1%) 101 (78.9%) 82 (68.3%)
Squamous cell carcinoma 2174 (35.8%) 93 (29.3%) 17 (13.3%) 21 (17.5%)
Large cell carcinoma 229 (3.8%) 10 (3.2%) 4 (3.1%) 9 (7.5%)
Adenosquamous carcinoma 155 (2.5%) 13 (4.1%) 6 (4.7%) 8 (6.7%)
pT
0 4 (0.1%) — — 1 (0.8%)
1 2569 (42.3%) 0 (0%) 24 (18.8%) 22 (18.3%)
2 2513 (41.3%) 0 (0%) 62 (48.4%) 43 (35.8%)
3 702 (11.5%) 0 (0%) 12 (9.4%) 28 (23.3%)
4 287 (4.7%) 317 (100%) 30 (23.4%) 26 (21.7%)
DNA 5 (0.15%) — — —
pN
0 3882 (63.8%) 120 (37.9%) 38 (29.7%) 44 (36.7%)
1 802 (13.2%) 55 (17.4%) 19 (14.8%) 18 (15%)
2 1261 (20.7%) 124 (39.1%) 52 (40.6%) 48 (40%)
3 95 (1.6%) 12 (3.8%) 7 (5.5%) 5 (4.2%)
X 27 (0.4%) 5 (1.6%) 9 (7%) 1 (0.8%)
DNA 13 (0.2%) 1 (0.3%) 3 (2.3%) 4 (3.3%)
DNA, data not available.
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follow-up date as the endpoint. The difference in survival was
determined by log-rank analysis. A p value of less than 0.05
was considered to indicate a statistically significant differ-
ence. All statistical analyses were performed using software
packages (SAS version 8.2, SAS Institute, Inc., Cary, NC;
and SPSS version 11.5, SPSS, Inc., Chicago, IL).
RESULTS
Table 1 shows the patient characteristics for each pop-
ulation. There were 6080 PM0 (93.2%), 317 PM1 (4.9%),
and 128 PM2 (2.0%) patients. There were 505 (7.7%) pa-
tients lost to follow-up. There were 3164 (48.5%) deaths.
Causes of deaths were recurrent lung cancer in 2282 (73.1%)
patients, other cancer in 109 (3.5%) patients, noncancerous
causes in 402 (12.9%) patients, and others in 371 (11.7%)
patients.
The 3- and 5-year survival rates were 65.4% and 55.1%
for PM0 patients, 37.5% and 26.8% for PM1 patients, and
33.0% and 22.5% for PM2 patients, respectively. There was
no statistically significant difference between PM1 and PM2
patients (p  0.298; Figure 1). Five-year survival rates were
72.1% for T1 patients, 46.4% for T2 patients, 34.0% for T3
patients, and 17.6% for T4 patients excluding PM1 pa-
tients (non-PM1 T4), respectively. The survival of patients
with PM1 was between that of the T3 and T4 patients without
PM1. Statistically significant survival differences were de-
tected between T3 and PM1 patients (p 0.032) and between
PM1 and non-PM1 T4 groups (p  0.0083; Figure 2).
The 5-year survival rates of PM2 patients and M1
patients excluding PM2 patients (non-PM2 M1) were 22.5%
and 20.5%, respectively, and there was no significant differ-
ence between the groups (p  0.434; Figure 3).
Five-year survival rates of PM1 patients with patholog-
ical N0, N1, and N2 node status were 45.8%, 25.3%, and
11.1%, respectively. Significant survival differences were
detected between each N-status group (Figure 4). Five-year
survival rates of PM2 patients with pathological N0, N1, and
N2 node status were 42.1%, 7.9%, and 10.0%, respectively.
Significant survival differences were detected between N0
and N1 (p  0.0016) and between N0 and N2 (p  0.0001)
groups, but there was no significant difference between N1
and N2 groups (p  0.644) (Figure 5). Five-year survival
rates of pathological N0 patients with PM0, PM1, and PM2
status were 68.0%, 45.8%, and 42.1%, respectively (Table 2).
There were significant survival differences between PM0 and
PM1 patients and between PM0 and PM2 patients (p  0.01,
respectively). There was no significant survival difference
between PM1 and PM2 patients (p  0.8775) (Figure 6). In
completely resected (R0) N0 patients, the 5-year survival
rates were 69.5% for PM0 patients, 47.3% for PM1 patients,
and 46.2% for PM2 patients, respectively. Statistically sig-
FIGURE 1. Survival curves of patients with PM0, PM1,
PM2. The differences in survival between patients with PM0
and PM1 and between patients with PM0 and PM2 were
significant (p  0.001, respectively); the difference in sur-
vival was not significant between patients with PM1 and
PM2 (p  0.298).
FIGURE 2. Survival curves of patients according to patho-
logical T status. There was a significant survival difference
between T1 and T2 patients, between T2 and T3 patients
(p  0.01, respectively), between T3 and PM1 patients (p 
0.032), and between PM1 and T4 patients excluding PM1
patients (p  0.01).
FIGURE 3. Survival curves of patients with PM2 and M1
excluding PM2 (non-PM2 M1). The difference in survival
between patients with PM2 and non-PM2 M1 was not sig-
nificant (p  0.434).
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nificant survival differences were detected between PM0 and
PM1 patients (p  0.01) and between PM0 and PM2 patients
(p  0.004). There was no significant difference between
PM1 and PM2 patients (p 0.922). In pathological N1 cases,
there were significant survival differences between PM0 and
PM1 patients and between PM0 and PM2 patients (p  0.01,
respectively). There was no significant survival difference
between PM1 N1 and PM2 N1 patients (p  0.0619). In N2
patients, there were significant survival differences between
PM0 and PM1 patients and between PM0 and PM2 patients
(p  0.01, respectively). There was no significant survival
difference between PM1 N2 and PM2 N2 patients (p 
0.998).
DISCUSSION
The current UICC TNM staging system for lung cancer
was published in 1997.4 The system classifies PM in the
primary tumor lobe as T4, and PM in different lobes as M1.
Several previous studies support the current UICC PM clas-
sification,6–9 but these studies were based on small numbers
of PM patients, ranging from 41 to 123. The present study has
the greatest number of PM patients ever reported on.
Differentiating PM from synchronous multiple primary
lung cancers is often difficult. The criteria proposed by
Martini and Melamed10 in 1975 are still the most practical
and commonly used. Pathologists at almost all institutions
involved in this study reported that they used these criteria.
Our analyses show a significant survival difference
between patients with PM and those without, whereas there
was no statistical difference between PM1 and PM2. When
analyzing survival rates of pathological N0 patients according
to PM status, there were significant survival differences
between PM0 and PM1 patients and between PM0 and PM2
patients, but there was no significant survival difference
between PM1 and PM2 patients. We conclude that PM is a
sign of advanced disease and that PM1 and PM2 should be
combined into a single PM category.
The 5-year survival rate was 34.0% for pathological T3
patients, 26.8% for PM1 patients, and 17.6% for non-PM1 T4
patients. PM1 patients fared significantly better than non-
PM1 T4 patients. PM2 patients, whose survival curve almost
overlapped that of PM1 patients, had almost the same out-
come as non-PM2 M1 patients. These findings do not agree
with the current UICC staging system,4 in which M1 patients,
including PM2 patients, are classified as stage IV, and in
FIGURE 4. Survival curves of PM1 patients according to
pathological N status. There were significant survival differ-
ences between N0 and N1 patients (p  0.0176) and be-
tween N1 and N2 patients (p  0.0114).
FIGURE 5. Survival curves of PM2 patients according to
pathological N status. There were significant survival differ-
ences between N0 and N1 patients (p  0.016) and be-
tween N0 and N2 patients (p  0.0001). There was no sig-
nificant survival difference between N1 and N2 patients (p 
0.644).
TABLE 2. Five-year Survival Rates of Intrapulmonary
Metastasis (PM) and Lymph Node Metastasis
PM0 (%) PM1 (%) PM2 (%)
0 68.0 45.8 42.1
1 44.6 25.3 7.9
2 26.2 11.1 10.2
FIGURE 6. Survival curves of pathological N0 patients ac-
cording to PM status. There were significant survival differ-
ences between PM0 and PM1 patients and between PM0
and PM2 patients (p  0.01, respectively). There was no sig-
nificant survival difference between PM1 and PM2 patients
(p  0.8775).
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which T4 patients, including PM1 patients, are classified as
stage IIIB. This may be partly explained by the fact these
non-PM1 T4 and non-PM2 M1 patients undergoing surgical
intervention were highly selected, thus creating to a certain
amount of bias. Further studies are necessary to decide the
appropriate classification of PM in the TNM staging system
revision that is scheduled for 2007.
Within the group of patients with PM1, there was a
significant difference in survival in relation to pathological N
status. In previous reports, there were no significant survival
differences between the different pathological N statuses.6,7,9
The large number of lung cancer patients with PM1 in the
present study resulted in a survival difference in relation to N
status being recognized.
In conclusion, there was no significant survival differ-
ence between NSCLC patients with PM1 and PM2. The
survival of patients with PM1 was between that of the T3
patients and the T4 patients excluding PM1. Further studies
are necessary to define PM classification in the TNM staging
system.
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